Exploratory identification of candidate biomarkers and molecular contributors to paclitaxel-induced peripheral neuropathy in patients with breast cancer through proteomic analysis - Top-Institutions - MDSpire

Exploratory identification of candidate biomarkers and molecular contributors to paclitaxel-induced peripheral neuropathy in patients with breast cancer through proteomic analysis

  • By

  • Nobuyoshi Kittaka

  • Hideaki Tahara

  • Takashi Akazawa

  • Yu Mizote

  • Takashi Kitajima

  • Keiichi Minami

  • Yurika Sugano

  • Takahiro Nakayama

  • June 16, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology

  • #2

    Osaka International Cancer Institute
    Osaka International Cancer Institute

    Osaka, Osaka

    Key Differentiators

    • Oncology

  • #3

    MD Anderson’s Institute for Data Science in Oncology (IDSO)
    MD Anderson’s Institute for Data Science in Oncology (IDSO)

    Houston, Texas

    Key Differentiators

    • Oncology

  • #4

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology

  • #5

    Department of Breast Medical Oncology
    Department of Breast Medical Oncology

    Houston, Texas

    Key Differentiators

    • Oncology

Original Source(s)

Exploratory identification of candidate biomarkers and molecular contributors to paclitaxel-induced peripheral neuropathy in patients with breast cancer through proteomic analysis

  • by Nobuyoshi Kittaka, Hideaki Tahara, Takashi Akazawa, Yu Mizote, Takashi Kitajima, Keiichi Minami, Yurika Sugano, Takahiro Nakayama

  • June 16, 2026

Related Content

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

The EU AI Act: implications and compliance guidance for healthcare facilities

Editorial: AntibodyPlus therapeutics in oncology: innovative mechanisms, therapeutic strategies, and clinical advances